Craig — stocks follow sentiment; biology follows
Post# of 157598
(Total Views: 503)
Posted On: 09/17/2025 6:33:51 PM
Re: craigakess #156982
Craig — stocks follow sentiment; biology follows data.
Here are primary sources on CCR5 biology and clinical signals across multiple disease areas. If you think “the world doesn’t believe in the science,” show contrary data—peer-reviewed, not vibes.
Pulmonary COVID-19 / ECMO case (UK):
• Case report: Critically ill patient on ECMO ~80 days received leronlimab, weaned off ECMO within ~5 days, later discharged. Peer-reviewed, PubMed Central. https://pmc.ncbi.nlm.nih.gov/articles/PMC7985604/ [oai_citation:0‡PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC7985604/?utm_source=chatgpt.com)
Pulmonary COVID-19 / Solid-organ transplant (Montefiore/Eintein team incl. Seethamraju):
• NEJM correspondence (kidney transplant recipients): six severely ill patients received the CCR5 inhibitor leronlimab on compassionate use. https://www.nejm.org/doi/full/10.1056/NEJMc2011117 [oai_citation:1‡New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMc2011117?utm_source=chatgpt.com)
• Montefiore/Eintein announcement of two FDA-cleared trials (mild–moderate and severe). https://www.prnewswire.com/news-releases/a-pr...63687.html [oai_citation:2‡PR Newswire](https://www.prnewswire.com/news-releases/a-promising-drug-for-the-treatment-of-severe-lung-inflammation-in-covid-19-patients-montefiore-einstein-scientists-lead-two-trials-of-leronlimab-301063687.html?utm_source=chatgpt.com)
• CD10 lung-transplant subset analysis (trial context). https://www.jhltonline.org/article/S1053-2498...0905-0/pdf [oai_citation:3‡JHLT Online](https://www.jhltonline.org/article/S1053-2498%2821%2900905-0/pdf?utm_source=chatgpt.com)
Infectious diseases Mechanism in COVID-19 (CCL5/CCR5 axis):
• Preprint with translational data showing CCL5/CCR5 disruption restores immune homeostasis and reduces plasma viral load in critical COVID-19. https://www.medrxiv.org/content/10.1101/2020.....full-text [oai_citation:4‡MedRxiv](https://www.medrxiv.org/content/10.1101/2020.05.02.20084673v1.full-text?utm_source=chatgpt.com)
Neuro Neuroinflammation / Neurology:
• Review: CCR5 antagonists (e.g., maraviroc) show neuroprotective potential in MS and other neuroinflammatory settings. Nature Reviews Neurology. https://pubmed.ncbi.nlm.nih.gov/26782333/ [oai_citation:5‡PubMed](https://pubmed.ncbi.nlm.nih.gov/26782333/?utm_source=chatgpt.com)
• 2025 review: CCR5 in dementia—CCR5 inactivation/deficiency may reduce inflammation and improve cognition. https://pmc.ncbi.nlm.nih.gov/articles/PMC12283282/ [oai_citation:6‡PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12283282/?utm_source=chatgpt.com)
Cancer Oncology (CCR5 axis in cancer):
• 2024 J Immunother Cancer: CCR5/CCL5 axis in metastatic colorectal cancer—links to prognosis and tumor microenvironment; therapeutic rationale for CCR5 blockade. https://jitc.bmj.com/content/12/5/e008722 [oai_citation:7‡Journals of the BMJ](https://jitc.bmj.com/content/12/5/e008722?utm_source=chatgpt.com)
• 2024/2023 peer-reviewed work shows CCR5 expression correlates with poor outcomes across tumors; CCR5 antagonism suppresses growth/metastasis in preclinical models. Examples: https://www.nature.com/articles/s41598-024-73251-9 ; https://www.sciencedirect.com/science/article...3524000296 ; https://pmc.ncbi.nlm.nih.gov/articles/PMC11797508/ [oai_citation:8‡Nature](https://www.nature.com/articles/s41598-024-73251-9?utm_source=chatgpt.com)
Fibrosis / MASLD-MASH:
• Human biomarker study: CCR5 mutation or pharmacologic blockade associated with improved hepatic fibrosis markers. Hepatology Communications. https://pmc.ncbi.nlm.nih.gov/articles/PMC6784280/ [oai_citation:9‡PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6784280/?utm_source=chatgpt.com)
• 2024 expert review: “Fatty liver disease—time to target CCR5?” synthesizes animal & human evidence linking CCR5 to inflammatory/fibrotic pathways in NAFLD/MASH. https://www.tandfonline.com/doi/full/10.1080/...24.2366880 (PDF: https://www.tandfonline.com/doi/pdf/10.1080/1...4.2366880) [oai_citation:10‡Taylor & Francis Online](https://www.tandfonline.com/doi/full/10.1080/14728222.2024.2366880?utm_source=chatgpt.com)
GastroIBD / Gut inflammation:
• Mechanistic overviews noting CCR5’s role in intestinal inflammation; preclinical amelioration with CCR5 blockade. https://www.frontiersin.org/journals/immunolo...56691/full ; https://academic.oup.com/ecco-jcc/article/12/...41/4904206 ; 2025 UC-specific CCL5/CCR5 review: https://www.sciencedirect.com/science/article...4924000947 [oai_citation:11‡Frontiers](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.956691/full?utm_source=chatgpt.com)
Real world data Named patient stories (UCLA):
• Samantha Mottet (Seal Beach) — multiple outlets reported Dr. Otto Yang (UCLA) obtained emergency use of leronlimab; she credits it with survival.
– CBS Los Angeles: https://www.cbsnews.com/losangeles/news/coron...eronlimab/ and https://www.cbsnews.com/losangeles/news/covid...eronlimab/
– Spectrum News 1: https://spectrumnews1.com/ca/southern-califor...9-recovery [oai_citation:12‡CBS News](https://www.cbsnews.com/losangeles/news/coronavirus-survivor-leronlimab/?utm_source=chatgpt.com)
Bottom line: CCR5 is a validated immunologic switch across inflammation, fibrosis, neuroinflammation, and the tumor microenvironment. Clinical signals (case reports, compassionate use, subsets) align with mechanism. Price quotes don’t nullify biology. If you’ve got peer-reviewed data contradicting any of the above, post it.
Here are primary sources on CCR5 biology and clinical signals across multiple disease areas. If you think “the world doesn’t believe in the science,” show contrary data—peer-reviewed, not vibes.
Pulmonary COVID-19 / ECMO case (UK):
• Case report: Critically ill patient on ECMO ~80 days received leronlimab, weaned off ECMO within ~5 days, later discharged. Peer-reviewed, PubMed Central. https://pmc.ncbi.nlm.nih.gov/articles/PMC7985604/ [oai_citation:0‡PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC7985604/?utm_source=chatgpt.com)
Pulmonary COVID-19 / Solid-organ transplant (Montefiore/Eintein team incl. Seethamraju):
• NEJM correspondence (kidney transplant recipients): six severely ill patients received the CCR5 inhibitor leronlimab on compassionate use. https://www.nejm.org/doi/full/10.1056/NEJMc2011117 [oai_citation:1‡New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMc2011117?utm_source=chatgpt.com)
• Montefiore/Eintein announcement of two FDA-cleared trials (mild–moderate and severe). https://www.prnewswire.com/news-releases/a-pr...63687.html [oai_citation:2‡PR Newswire](https://www.prnewswire.com/news-releases/a-promising-drug-for-the-treatment-of-severe-lung-inflammation-in-covid-19-patients-montefiore-einstein-scientists-lead-two-trials-of-leronlimab-301063687.html?utm_source=chatgpt.com)
• CD10 lung-transplant subset analysis (trial context). https://www.jhltonline.org/article/S1053-2498...0905-0/pdf [oai_citation:3‡JHLT Online](https://www.jhltonline.org/article/S1053-2498%2821%2900905-0/pdf?utm_source=chatgpt.com)
Infectious diseases Mechanism in COVID-19 (CCL5/CCR5 axis):
• Preprint with translational data showing CCL5/CCR5 disruption restores immune homeostasis and reduces plasma viral load in critical COVID-19. https://www.medrxiv.org/content/10.1101/2020.....full-text [oai_citation:4‡MedRxiv](https://www.medrxiv.org/content/10.1101/2020.05.02.20084673v1.full-text?utm_source=chatgpt.com)
Neuro Neuroinflammation / Neurology:
• Review: CCR5 antagonists (e.g., maraviroc) show neuroprotective potential in MS and other neuroinflammatory settings. Nature Reviews Neurology. https://pubmed.ncbi.nlm.nih.gov/26782333/ [oai_citation:5‡PubMed](https://pubmed.ncbi.nlm.nih.gov/26782333/?utm_source=chatgpt.com)
• 2025 review: CCR5 in dementia—CCR5 inactivation/deficiency may reduce inflammation and improve cognition. https://pmc.ncbi.nlm.nih.gov/articles/PMC12283282/ [oai_citation:6‡PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12283282/?utm_source=chatgpt.com)
Cancer Oncology (CCR5 axis in cancer):
• 2024 J Immunother Cancer: CCR5/CCL5 axis in metastatic colorectal cancer—links to prognosis and tumor microenvironment; therapeutic rationale for CCR5 blockade. https://jitc.bmj.com/content/12/5/e008722 [oai_citation:7‡Journals of the BMJ](https://jitc.bmj.com/content/12/5/e008722?utm_source=chatgpt.com)
• 2024/2023 peer-reviewed work shows CCR5 expression correlates with poor outcomes across tumors; CCR5 antagonism suppresses growth/metastasis in preclinical models. Examples: https://www.nature.com/articles/s41598-024-73251-9 ; https://www.sciencedirect.com/science/article...3524000296 ; https://pmc.ncbi.nlm.nih.gov/articles/PMC11797508/ [oai_citation:8‡Nature](https://www.nature.com/articles/s41598-024-73251-9?utm_source=chatgpt.com)
Fibrosis / MASLD-MASH:
• Human biomarker study: CCR5 mutation or pharmacologic blockade associated with improved hepatic fibrosis markers. Hepatology Communications. https://pmc.ncbi.nlm.nih.gov/articles/PMC6784280/ [oai_citation:9‡PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6784280/?utm_source=chatgpt.com)
• 2024 expert review: “Fatty liver disease—time to target CCR5?” synthesizes animal & human evidence linking CCR5 to inflammatory/fibrotic pathways in NAFLD/MASH. https://www.tandfonline.com/doi/full/10.1080/...24.2366880 (PDF: https://www.tandfonline.com/doi/pdf/10.1080/1...4.2366880) [oai_citation:10‡Taylor & Francis Online](https://www.tandfonline.com/doi/full/10.1080/14728222.2024.2366880?utm_source=chatgpt.com)
GastroIBD / Gut inflammation:
• Mechanistic overviews noting CCR5’s role in intestinal inflammation; preclinical amelioration with CCR5 blockade. https://www.frontiersin.org/journals/immunolo...56691/full ; https://academic.oup.com/ecco-jcc/article/12/...41/4904206 ; 2025 UC-specific CCL5/CCR5 review: https://www.sciencedirect.com/science/article...4924000947 [oai_citation:11‡Frontiers](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.956691/full?utm_source=chatgpt.com)
Real world data Named patient stories (UCLA):
• Samantha Mottet (Seal Beach) — multiple outlets reported Dr. Otto Yang (UCLA) obtained emergency use of leronlimab; she credits it with survival.
– CBS Los Angeles: https://www.cbsnews.com/losangeles/news/coron...eronlimab/ and https://www.cbsnews.com/losangeles/news/covid...eronlimab/
– Spectrum News 1: https://spectrumnews1.com/ca/southern-califor...9-recovery [oai_citation:12‡CBS News](https://www.cbsnews.com/losangeles/news/coronavirus-survivor-leronlimab/?utm_source=chatgpt.com)
Bottom line: CCR5 is a validated immunologic switch across inflammation, fibrosis, neuroinflammation, and the tumor microenvironment. Clinical signals (case reports, compassionate use, subsets) align with mechanism. Price quotes don’t nullify biology. If you’ve got peer-reviewed data contradicting any of the above, post it.
(10)
(0)